StockData

BioNexus Gene Lab vs YD Bio

BGLC and YDES side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How BGLC and YDES compare

YD Bio grew revenue faster over the last twelve months (16.9% versus −67.3% for BioNexus Gene Lab).

BioNexus Gene Lab keeps more of each dollar of sales as profit, with a net margin of −82.4% compared with −1393% at YD Bio.

BioNexus Gene Lab scores higher on the StockData Score (8 against 5 for YD Bio), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricBGLCYDES
Size and price
Market cap$2.4M–
Share price$0.821$4.88
Change, 1 year−83.0%−44.8%
Change, 5 years−99.6%−52.0%
Beta (5Y)0.870.10
Employees613
StockData Score
Total score8 (better)5
Valuation score3 (better)0
Growth score00
Performance score00
Health score55
Dividend score00
Valuation
P/S0.8×–
P/B0.3×–
FCF yield−35.4%–
Fair value$7.45–
Margin of safety89.0%–
Growth
Revenue growth (TTM)−67.3%16.9% (better)
Revenue growth, 5Y average−8.2%–
Profitability
Gross margin12.3%28.1% (better)
Operating margin−81.8% (better)−883%
Net margin−82.4% (better)−1393%
FCF margin−27.3% (better)−1347%
Return on equity−33.7% (better)−174%
Return on invested capital−32.3% (better)−130%
Financial health
Debt / equity0.000.00
Current ratio6.08 (better)5.23
Altman Z-score0.32–
Piotroski F-score4 (better)2
Dividends and buybacks
Shareholder yield0.00%–
Ownership
Held by institutions0.49%–
Held by insiders31.0%92.8%
Insider net buying, 12 months–$129K
Short interest, % of float0.16%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.